The residue of solvent in APIs is one of the key issues to be mindful of during drug manufacturing. When solvent residue exists in the APIs or formulations, it may have adverse effects on the stability, purity, and efficacy of the drugs. Overcoming the difficulties of solvent residue in APIs involves multiple aspects, such as selecting appropriate solvents, optimizing synthesis conditions, and employing effective methods for solvent removal. At the same time, it is essential to employ scientific testing methods to monitor and ensure that solvent residues are within acceptable limits. Establishing highly sensitive and accurate analytical detection methods is indispensable to meet international standards for residual solvent detection, thus safeguarding the safety and efficacy of medication for patients.
Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs
On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs , mRNA vaccines , small nucleic acid drugs , PROTAC , and CGT technical service platform that have helped 421 INDs obtain clinical approval. It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

评论
发表评论